Nevada Legislature-posted Board of Pharmacy meeting agenda/workshop materials indicate proposed amendments to NAC 453 to add the nitazene analogs N‑pyrrolidino metonitazene and N‑pyrrolidino protonitazene to Schedule I. This signals additional controlled substance scheduling changes progressing through the state administrative process. If adopted, these substances would be regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation (NAC 453), impacting compliance obligations for entities that may handle or encounter these substances (e.g., laboratories, healthcare/controlled-substance registrants, and enforcement).
The Nevada State Board of Pharmacy issued a Notice of Hearing/Intent to act upon a regulation proposing amendments to NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada’s Schedule I list under the Uniform Controlled Substances Act framework. The notice schedules a public hearing (March 5, 2026). If adopted, these substances would become subject to Schedule I restrictions, affecting controlled substance compliance programs (e.g., prohibitions/controls on possession, handling, distribution, and associated enforcement exposure).
An informational statement for an adopted Nevada State Board of Pharmacy regulation reports an amendment to NAC 453.510 (Schedule I) adding ethylphenidate and 2‑methyl AP‑237 to Nevada’s Schedule I list. These additions expand substances regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation, affecting compliance for any organization potentially encountering these substances (e.g., prohibitions and controls related to possession, distribution, and enforcement consequences). The document states the change is intended to keep Nevada in conformity with federal controlled substance scheduling.
The Nevada State Board of Pharmacy published a public hearing notice and proposed regulation text to amend NAC 453.510 to add ethylphenidate and 2‑methyl AP‑237 to Schedule I under Nevada’s Uniform Controlled Substances Act implementation. The notice sets a public hearing for Dec. 4, 2025. (Note: a separate later Nevada Register informational statement indicates these substances were subsequently adopted into Schedule I; this record captures the earlier proposal and comment/hearing step.)
Nevada Attorney General Opinion No. 2025-01 provides an official legal interpretation addressing issues involving controlled substances under NRS 453 (Nevada Uniform Controlled Substances Act), including discussion of authorization/registration considerations relevant to prescribing/possession in the context analyzed by the opinion. While not a codified amendment, the opinion can materially affect compliance expectations for regulated practitioners and entities by clarifying legal interpretation applied in Nevada.